Multiple Sclerosis Journal – Experimental, Translational and Clinical | |
Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM: | |
Minhua Yang1  Jing L Marantz2  Douglas L Arnold2  Amit Bar-Or3  Gavin Giovannoni4  Ralf Gold5  Ludwig Kappos6  | |
[1] Biogen, USA;Montreal Neurological Institute, McGill University, Canada;NeuroRx Research, Montreal, Canada;Queen Mary University London, UK;St Josef Hospital, Ruhr University, Germany;University Hospital, Basel Neurology, Switzerland | |
关键词: Delayed-release dimethyl fumarate; multiple sclerosis; disability evaluation; Multiple Sclerosis Functional Composite; disease progression; neuropsychological tests; | |
DOI : 10.1177/2055217316634111 | |
学科分类:医学(综合) | |
来源: Sage Journals | |
【 摘 要 】
The effect of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on the Multiple Sclerosis Functional Composite (MSFC) was assessed using integrated Phase 3 DEFINE and CONFIRM data. Patients treated with DMF (nâ=â769) demonstrated significant superiority on the MSFC, and each component, compared with placebo (nâ=â771) over two years: mean change for DMF vs placebo was 0.054 vs â0.053 on MSFC; â0.088 vs â0.286 on Timed 25-Foot Walk, 0.047 vs 0.003 on 9-Hole Peg Test and 0.178 vs 0.123 on Paced Auditory Serial Addition Test. DMF was an efficacious treatment for patients with MS.
【 授权许可】
CC BY-NC
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201902020682692ZK.pdf | 110KB | download |